DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of ...
IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. Blood glucose sensor and transmitter ...
LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...
New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...
2don MSN
Dexcom outlines 2026 revenue growth of 11%-13% with G7 15 day rollout and international expansion
Q4 2025 Management View Jacob Leach, President, CEO & Director, marked his first call as CEO by outlining three strategic ...
DexCom, Inc. DXCM announced that its DexCom ONE continuous glucose monitoring (CGM) system has been launched in France for people with diabetes. The latest CGM sensor from the company’s portfolio has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results